Shezad Malik Law Firm Dr Shezad Malik Law Firm has offices based in Fort Worth and Dallas and represents people who have suffered catastrophic and serious personal injuries including wrongful death, caused by the negligence or recklessness of others. We specialize in Personal Injury trial litigation and focus our energy and efforts on those we represent.

Articles Tagged with Invokana

Invokana Injury Lawsuit. Martha Williams, from Tennessee, recently filed an Invokana product liability and personal injury lawsuit against Janssen Pharmaceuticals and it’s parent company, Johnson & Johnson. According to Williams, in her Invokana injury lawsuit, the serious side effects of Invokana caused her to develop acute renal failure, and urinary tract infection.

Invokana Injury Lawsuit

Invokana Injury Lawsuit. Invokana linked to kidney failure, leg amputations and diabetic ketoacidosis according to lawsuits.

What is Invokana?

Invokana Wrongful Death Lawsuit. Scott Martin from Alabama alleges that the side effects of the blockbuster diabetic drug Invokana caused the wrongful death of his wife. According to Martin, his wife suffered severe diabetic ketoacidosis and congestive heart failure, leading to her death.

Invokana Wrongful Death Side Effects

Invokana Wrongful Death Side Effects. Invokana linked to kidney failure, leg amputations, and diabetic ketoacidosis according to lawsuits.

Martin filed his claim, on behalf of himself and his late wife, Sheila Martin, in the U.S. District Court for the District of New Jersey, naming Johnson & Johnson and its Janssen Pharmaceuticals subsidiary as defendants.

Invokana lawsuitsThe number of lawsuits filed by people who say they suffered serious side effects after taking Invokana (canagliflozin) continues to grow in Philadelphia amid rising safety concerns. Attorneys are also investigating other drugs in the Type 2 diabetes drug class known SGLT2 inhibitors.

While attorneys across the country are filing lawsuits on behalf of local plaintiffs, Pennsylvania is seeing a large number of cases. Dozens of cases made their way to Philadelphia. An attorney family with the cases told a reporter at the Legal Intelligencer that more than 150 suits are pending in Missouri and Illinois.

Attorneys say a judge may consolidate the cases if the volume continues to grow.

Invokana lawsuitsTwo years after the U.S. Food and Drug Administration (FDA) approved Johnson & Johnson’s Invokana, the FDA issued a drug safety communication that warned doctors and patients that Invokana may lead to diabetic ketoacidosis (DKA). According to recent lawsuits, the makers of Invokana knew or should have known about diabetic ketoacidosis but failed to warn consumers.

Invokana is a new class of Type 2 diabetes drug called sodium-glucose co-transporter 2 (SGLT2). This class of Type 2 diabetes drugs work by stopping glucose from being reabsorbed into the blood. The FDA approved Invokana in 2013. In May 2015 the FDA release a statement warning patients and doctors that SGLT2 drugs may lead to DKA. If DKA is left untreated, it can be fatal.

In December 2015, the FDA ordered manufacturers of SGLT2 inhibitors to add warnings regarding the risk of urinary tract infection and ketoacidosis to the drugs’ labels.

Invokana lawsuits are on the rise.

Invokana lawsuits are on the rise.

Invokana is a new class of Type 2 diabetes drug called sodium-glucose co-transporter 2 (SGLT2). This class of Type 2 diabetes drugs work by stopping glucose from being reabsorbed into the blood. The FDA approved Invokana in 2013 and has grown to over 2.7 million prescriptions per year.

In May 2015 the FDA release a statement warning doctors and patients that SGLT2 drugs may lead to DKA. If DKA is left untreated, it can be fatal.

texas_dangeous_drug_attorneyThe Food and Drug Administration (FDA) issued a drug safety communication stating that it has revised the warning labels of SGLT2 inhibitors, including Invokana, to include information about acute kidney injury.

According to a press release from the FDA, between March 2013 and October 2015, the agency received reports of 101 confirmed cases of acute kidney injury, some of which required dialysis and hospitalization, related to Invokana/Invokamet (canagliflozin, Janssen Pharmaceuticals) and Farxiga/Xigduo XR (dapagliflozin, Bristol-Myers Squibb/AstraZeneca).

The communication advised health care professionals to “consider factors that may predispose patients to acute kidney injury prior to starting them on canagliflozin or dapagliflozin.” These include lower blood volume; chronic kidney insufficiency; congestive heart failure; and taking medications such as diuretics, ACE inhibitors, angiotensin receptor blockers and nonsteroidal anti-inflammatory drugs.

Invokana lawsuitsInvokana is a new class of Type 2 diabetes drug called sodium-glucose co-transporter 2 (SGLT2). This class of Type 2 diabetes drugs work by stopping glucose from being reabsorbed into the blood. The FDA approved Invokana in 2013. In May 2015 the FDA release a statement warning doctors and patients that SGLT2 drugs may lead to DKA. If DKA is left untreated, it can be fatal.

In December 2015, the FDA ordered manufacturers of SGLT2 inhibitors to add warnings regarding the risk of urinary tract infection and ketoacidosis to the drugs’ labels.

Diabetic ketoacidosis occurs when the body does not have enough insulin to manage glucose levels. During diabetic ketoacidosis the body starts developing a waste product known as acidic ketone bodies by burning fatty acids. Ketones are what cause symptoms of ketoacidosis. These symptoms include abdominal pain, fatigue, confusion, vomiting, and dehydration. In some rare cases, ketoacidosis can cause coma or death.

Two years after the U.S. Food and Drug Administration (FDA) approved Johnson & Johnson’s Invokana, the FDA issued a drug safety communication that warned doctors and patients that Invokana may lead to diabetic ketoacidosis (DKA).

Invokana Lawsuits

Invokana lawsuits are on the rise.

Invokana is a new class of Type 2 diabetes drug called sodium-glucose co-transporter 2 (SGLT2). This class of Type 2 diabetes drugs work by stopping glucose from being reabsorbed into the blood. The FDA approved Invokana in 2013. In May 2015 the FDA release a statement warning doctors and patients that SGLT2 drugs may lead to DKA. If DKA is left untreated, it can be fatal.

According to the FDA recent warning, there are serious issues and side effects with the new class of medications used to treat type 2 diabetes.

Invokana Diabetic Ketoacidosis AttorneyWhat is Invokana?

Johnson & Johnson’s Janssen Pharmaceuticals unit manufactures and distributes Invokana (canagliflozin), for patients with type-2 diabetes, to control their blood-sugar levels. The drug has achieved blockbuster status, in that it is set to blow past a billion dollars in sales in 2015.

Contact Information